Drugs / OmnImmune®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03790072 | Nov 2018 → Mar 2021 | acute myeloid leukemia | TC Biopharm | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OmnImmune | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03790072 ↗ |
| Modality | Cell therapy | “expanded gamma delta T lymphocytes” NCT03790072 ↗ |